The Study of Genes Localization for Female Pelvic Floor Dysfunction (PFD POP UI)

Zhiqing, Liang

Status: Unknown

Conditions: Female Pelvic Floor Dysfunction

Study type: Observational

Funder types: Other

Identifiers

NCT02166528

002

Details and patient eligibility

About

Female pelvic floor dysfunction (FPD) is due to defects in the pelvic support structures, degradation, damage or dysfunction. The main problem of which is pelvic organ prolapse(POP), urinary incontinence(UI) and genital tract injury. Although it does not pose a serious threat to life, but affect the patient's quality of life seriously in the physical, psychological, social behavior and other aspects. With the growing aging population, the incidence rate has gradually increased, and increasing demands for people's quality of life simultaneously, more and more attention was raised to PFD as common chronic diseases.

In recent years, the basic research, epidemiology, prevention, diagnosis and treatment of PFD have made great progress, especially in developing gynecological urology theory and reconstructive pelvic surgery. But overall the basic research of PFD is lagging behind, especially susceptibility gene localization and functional studies did not get enough attention.

Enrollment: 200 estimated patients

Sex: Female

Ages: 30 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. female aging from 30 to 70-year old;
2. preoperative diagnosis of gynecologic malignancies;
3. have the ability to comply with Research programs;
4. voluntarily participate in the study and signed an informed consent form

Exclusion criteria

1. patients with severe cardiovascular diseases, kidney, liver and other vital organs diseases, bone marrow disease and mental illness;
2. patients suffering from autoimmune diseases;
3. patients with acute infectious disease or infection early phase of infection;
4. patients with urinary tract infection;
5. patients with infection or erosion of ano-genital skin;
6. for any other reason, the researchers considered unsuitable for inclusion.

Trial design

200 participants in 2 patient groups

experiment group

Description:

patients with FPFD

control group

Description:

patients without FPFD